Preparation and bioevaluation of 99mTc-Annexin B1 as a novel radiotracer for apoptosis imaging

Quan-yong LUO,Zhi-yong ZHANG,Fang WANG,Yi ZHANG,Han-kui LU,Shu-han SUN,Rui-sen ZHU
DOI: https://doi.org/10.3321/j.issn:1003-3289.2008.08.009
2008-01-01
Abstract:Objective Annexin B1,a novel Ca2+-dependent phosphatidylserine(PS)-binding protein,has been shown to have a high affinity for PS exposed on the surface of apoptotic cells or activated platelets.The aim of this study was to develop and bioevaluate a Annexin B1 based PS-targeting radiotracer.Methods Annexin B1 was directly radiolabeled with technetium-99m using stannous chloride as reducing agent in the presence of citrate.Binding assay with human activated platelets was used to evaluate the biological activity of 99mTc-Annexin B1 in vitro.Biodistribution of this radioligand was studied in normal mice.The potential of 99mTc-Annexin B1 to detect apoptosis in vivo was evaluated in dexamethasone-inducecd thymus apoptotic mice and anti-Fas antibody induced liver apoptotic mice.Results The labeling procedure yielded 99mTc-Annexin B1 with high radiochemical purity and good in vitro stability.Platelets binding assay indicated that 99mTc-Annexin B1 retained its PS binding activity in vitro.99mTc-Annexin B1 is rapidly cleared from the blood and predominantly accumulates in the kidney.The uptake of mouse thymus increased markedly at 18 hours after the administration of dexamethasone compared with control mice.Radionuclide imaging showed a markedly increased uptake of 99mTc-Annexin B1 in the liver of anti-Fas antibody treated mice compared with the control.Conclusion These data suggest that 99mTc-Annexin B1 retain its in vitro and in vivo biological activities.It may therefore be useful as a novel radioligand for the noninvasive imaging of PS externalization associated with apoptosis.
What problem does this paper attempt to address?